中国麻风皮肤病杂志 ›› 2024, Vol. 40 ›› Issue (10): 744-748.doi: 10.12144/zgmfskin202410744

• 综述 • 上一篇    下一篇

原发性皮肤淀粉样变治疗进展

白璐,张丽君,朱才勇   

  1. 中国人民解放军陆军第八十集团军医院皮肤病科，山东潍坊，261031
  • 出版日期:2024-10-15 发布日期:2024-08-29

Update of the treatment for primary cutanious amyloidosis

BAI Lu, ZHANG Lijun, ZHU Caiyong   

  1. Department of Dermatology, The Hospital of No.80 Group Amy of PLA, Weifang 261031, China
  • Online:2024-10-15 Published:2024-08-29

PDF (PC)

395

摘要： 原发性皮肤淀粉样变（PCA）引起的瘙痒难以忍受，目前对治疗的总体反应不佳，严重影响了患者的生活质量。近年来发现系统使用度普利尤单抗、乌帕替尼、巴瑞替尼、阿布昔替尼，局部使用氨甲环酸、加巴喷丁、二甲基亚砜溶液及火针疗法、点阵二氧化碳激光等取得了显著的治疗效果。本文对PCA的治疗进展进行综述，为临床提供参考。

关键词: 原发性皮肤淀粉样变, 度普利尤单抗, 乌帕替尼, 氨甲环酸

Abstract: The itching caused by primary cuticular amyloidosis (PCA) is unbearable, and the response to the treatment is currently poor, which greatly affected the patient's quality of life. In recent years, it has been found that the significant therapeutic effects by systemic use of system dupilumab, upadacitinib, baricitinib, and abrocitinib, as well as local use of tranexamic acid, gabapentin, dimethyl sulfoxide solution, fire needle therapy, and lattice carbon dioxide laser. The update of the treatment of PCA is reviewed in this paper to provide reference for clinical practice.

Key words: primary cutanious amyloidosis, dupilumab, upadacitinib, tranexamic acid